Mantra Bio Raises $9 Million in Series A-2 Financing to Advance Development of Lead Targeted Exosome Therapeutics Program; Emerging Therapeutic Pipeline Focused on Ophthalmology and Infectious Disease

Exosome

On January 4, 2023, Mantra Bio, headquartered in South San Francisco, announced it has raised $9 million in a Series A-2 financing to advance the development of its lead targeted exosome therapeutics program. New investor, Samsung Securities, joined existing investors, including 8VC, Viking Global Investors, Illumina, BoxGroup, and Allen & Company in the financing round. The company's overall Series A funding, including a $25 million Series A-1, totals $34 million. "Mantra Bio has made significant progress in building out REVEALâ„¢, our exosome engineering platform, and leveraging the technology to advance two exosome-based therapeutic programs through preclinical discovery, with a development candidate selected for our lead program aimed at ophthalmic diseases," said Alex Mok, Mantra Bio's CEO and co-founder. "The new Series A-2 funds will enable Mantra Bio to advance our lead development candidate through IND-enabling studies. The support from Samsung Securities and our existing investors is a strong vote of confidence in the potential of our platform, our therapeutic pipeline strategy, and our progress."

Login Or Register To Read Full Story